Multiple launches to boost Cipla's margin prescription

The shares of pharma major Cipla slipped by about 4 per cent on Tuesday, after gaining over 5.6 per cent a day earlier.

- RAM PRASAD SAHU

On Monday, it was among the top gainers in the BSE 100 Index on the back of the fourth-quarter results reported on Friday.

TH I major A While the March quarter performance was slightly below estimates, the stock gains were on the back of multiple launches, improved outlook and higher margin guidance for FY25.

Revenues in the quarter were up 7 per cent over the year-ago period while operating profit gained 12 per cent missing Street estimates. Adjusted for one-off gains, the net profit was up 22 per cent and was boosted by higher other income and lower interest costs.

The revenue was led by steady growth in the US market which was up 12 per cent Y-o-Y. This was due to improved demand in peptides, respiratory products and sales of generic version of cancer drug, Revlimid.

Active pharmaceutical ingredients business led on the sales front with a growth of 42 per cent while the domestic sales were up 7 per cent Y-o-Y.

Sales growth for FY24 was, however, strong at 13 per cent while operating profit too was strong at 23 per cent.